Vanguard Group’s Loxo Oncology, Inc LOXO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-2,789,978
| Closed | -$391M | – | 4155 |
|
|
2018
Q4 | $391M | Buy |
2,789,978
+119,955
| +4% | +$18.2M | 0.02% | 831 |
|
|
2018
Q3 | $456M | Buy |
2,670,023
+281,635
| +12% | +$47.3M | 0.02% | 839 |
|
|
2018
Q2 | $414M | Buy |
2,388,388
+274,225
| +13% | +$41.2M | 0.02% | 878 |
|
|
2018
Q1 | $244M | Buy |
2,114,163
+141,244
| +7% | +$15M | 0.01% | 1158 |
|
|
2017
Q4 | $166M | Buy |
1,972,919
+549,158
| +39% | +$45.8M | 0.01% | 1426 |
|
|
2017
Q3 | $131M | Buy |
1,423,761
+509,042
| +56% | +$39.5M | 0.01% | 1546 |
|
|
2017
Q2 | $73.4M | Buy |
914,719
+181,471
| +25% | +$10.1M | ﹤0.01% | 1830 |
|
|
2017
Q1 | $30.9M | Buy |
733,248
+219,837
| +43% | +$9.05M | ﹤0.01% | 2231 |
|
|
2016
Q4 | $16.5M | Buy |
513,411
+8,270
| +2% | +$212K | ﹤0.01% | 2505 |
|
|
2016
Q3 | $13.2M | Buy |
505,141
+5,858
| +1% | +$153K | ﹤0.01% | 2548 |
|
|
2016
Q2 | $11.6M | Buy |
499,283
+221,901
| +80% | +$5.52M | ﹤0.01% | 2583 |
|
|
2016
Q1 | $7.58M | Buy |
277,382
+24,797
| +10% | +$519K | ﹤0.01% | 2757 |
|
|
2015
Q4 | $7.19M | Buy |
252,585
+95,426
| +61% | +$2.56M | ﹤0.01% | 2817 |
|
|
2015
Q3 | $2.75M | Sell |
157,159
-20,319
| -11% | -$398K | ﹤0.01% | 3228 |
|
|
2015
Q2 | $3.2M | Buy |
177,478
+133,121
| +300% | +$1.82M | ﹤0.01% | 3211 |
|
|
2015
Q1 | $552K | Buy |
44,357
+8,650
| +24% | +$108K | ﹤0.01% | 3802 |
|
|
2014
Q4 | $420K | Buy |
+35,707
| New | +$416K | ﹤0.01% | 3779 |
|
Other funds holding LOXO
Vanguard Group's LOXO Position: Q1 2019 in Review
Vanguard Group sold out of Loxo Oncology, Inc (LOXO) in Q1 2019, closing a stake of 2,789,978 shares — an estimated $391M sold.
Vanguard Group first reported a position in LOXO in Q4 2014 and held it in 17 quarters. The position peaked at $456M in Q3 2018. 1 fund tracked by Wall St. Rank holds LOXO as of Q1 2019.
- Vanguard Group reported no remaining Loxo Oncology, Inc position as of Q1 2019 after selling out during the quarter.
- Vanguard Group sold 2,789,978 Loxo Oncology, Inc shares in Q1 2019, an estimated $391M.
- Vanguard Group first reported a position in Loxo Oncology, Inc in Q4 2014 and held it in 17 quarters.
- Vanguard Group's Loxo Oncology, Inc position peaked at $456M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Loxo Oncology, Inc as of Q1 2019.
Based on Vanguard Group's 13F filing for Q1 2019, filed 15 May 2019.